Israeli company Alcobra Ltd., which develops treatments for Attention Deficit Hyperactive Disorder (ADHD), has filed a draft prospectus with the American SEC. The Israeli company plans to hold an IPO on Nasdaq at a company value of $100 million, and hopes to raise $15-20 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments